2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 002

Assessing Juvenile Idiopathic Arthritis Healthcare Costs to Advance Value-Based Care
Abstract Number: 122

Assessing the Relationship Between Multidimensional Area Level Indicators and Lupus Disease Activity in Children
Abstract Number: 038

Assessment of Disease Activity and Skeletal Damage in Pediatric Chronic Nonbacterial Osteomyelitis and the Effects of Different Treatment Regimens
Abstract Number: 053

Association between Childhood Opportunity Index and Disparities in Health Care Access and Utilization in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 075

Association of Anti-Cytokine Biologics and JAK inhibitors with Bronchoalveolar Fluid Cytokine Profiles in Patients with Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD)
Abstract Number: 047

Association of anti-DFS70 with autoimmune diseases in children
Abstract Number: 004

Barriers and Facilitators to Teratogenicity Knowledge and Application among Adolescents and Young Adults with Rheumatic Disease
Abstract Number: 008

Body Mass Index, Neighborhood Opportunity, and Outcomes of Childhood-Onset Lupus
Abstract Number: 014

Bone Microarchitecture Impairment in Juvenile Systemic Lupus Erythematosus Patients: A Comparative Study
Abstract Number: 120

Bridging Evidence and Practice: New Institutional Pathway Increases Primary Intensification Rates for Children with High-Risk Kawasaki Disease
Abstract Number: 020

Building Consensus on Key Research Domains and Research Topics in Childhood-onset Neuropsychiatric Lupus: An International Prioritization Initiative
Abstract Number: 112

Burden of Latent and Active TB in Pediatric TNF-Inhibitor Therapy: A Decade of Real-World Data from a Tertiary Care Centre
Abstract Number: 052

Case Series: Treatment of Refractory Lung Disease in Systemic Juvenile Idiopathic Arthritis with Cyclophosphamide and Rituximab Combination Therapy
Abstract Number: 043

Challenges of Cognitive Screening and Formal Neuropsychological Evaluation in Youth with Childhood-Onset Systemic Lupus Erythematosus: A Survey of CARRA Providers
Abstract Number: 090

Characterizing CNS MRI Abnormalities in Pediatric ANCA-Associated Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].